Equity Overview
Price & Market Data
Price: $0.93
Daily Change: +$0.0802 / 8.62%
Daily Range: $0.90 - $0.97
Market Cap: $47,980,132
Daily Volume: 20,317
Performance Metrics
1 Week: 3.65%
1 Month: 0.88%
3 Months: 6.76%
6 Months: -23.44%
1 Year: -85.45%
YTD: -33.35%
Company Details
Employees: 131
Sector: Health technology
Industry: Biotechnology
Country:
Details
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.